DETROIT – Registration is now open for the 11th The Eye and The Chip research congress, which will take place Nov. 10-12, 2019 at The Henry Hotel in Dearborn, Michigan. This year’s research congress will focus on the relationship between neurobiology and nanoelectronics with respect to artificial vision. The ultimate goal of the research congress is to advance progress toward artificial vision for many people who suffer from blindness.
“Results from this research congress will help move us towards the day when many people who are currently blind will be able to recover some level of useful vision,” said Phillip Hessburg, M.D., Medical Director of the Detroit Institute of Ophthalmology, the research arm of Henry Ford Health System’s Department of Ophthalmology. “At this collaborative event, the Detroit Institute of Ophthalmology brings together more than 30 authorities from various vision science and technology fields.”
The Eye and the Chip is dedicated to fostering collaborative relationships between major programs in Europe, America, Asia and Australia that are working to make advances and identify challenges remaining in the global pursuit of true artificial vision. The research congress also seeks to present outcomes of device implantation where it is occurring and identify progress toward FDA approval of various visual neuro-prosthetic devices implantated in humans.
At the end of this three-day research congress, attendees will:
- Have a clear understanding of which blind patients will benefit from a visual neuro-prosthetic device.
- Have reviewed progress in the field of visual neuro-prosthetic device development and challenges of surgical implementation.
- Know how nanoelectronic visual neuroprosthetic devices compare with other artificial vision initiatives. (i.e. gene therapy, optogenetic therapy and stem cell therapy)
- Have viewed the development process of a complex medical device and will recognize the role played by the FDA in bringing forth safe and effective medical devices.
- Be fully-aware of which patients will benefit from a device within the eye, and which patients will benefit only by a device interfacing directly with the visual cortex of the brain.
- Have formed additional collaborative relationships which will serve to accelerate the process of device development and implantation
Presenters from around the world will take the stage at this year’s research congress. For an up-to-date and complete list of presenters and topics, and access to the full congress agenda, please visit the confirmed speakers website. 21.50 AMA PRA Category 1 Credit(s) (TM) are available, as are 21.50 Non-Physician Credit Hours.
For more information, go to henryford.com/TheEyeAndTheChip or contact program coordinator Roseanne Horne at 313-936-1968 or firstname.lastname@example.org.
MEDIA CONTACT: Jeff Adkins / (586) 307-2027 / email@example.com
About Henry Ford Health System and the Detroit Institute of Ophthalmology:
Henry Ford Health System is a six-hospital system headquartered in Detroit, Michigan. It is one of the nation’s leading comprehensive, integrated health systems, recognized for clinical excellence and innovation. Henry Ford provides both health insurance and health care delivery, including acute, specialty, primary and preventive care services backed by excellence in research and education. Henry Ford Health System is led by President & CEO Wright Lassiter III. Visit HenryFord.com to learn more.
The Detroit Institute of Ophthalmology (DIO) is the research arm of the Henry Ford Department of Ophthalmology, committed to the education and support of the visually impaired, helping them maintain dignity and independence, while learning to how to live productively in a sighted world. The DIO is also a world leader in facilitating collaborative research, sponsoring two international research congresses. Visit HenryFord.com/DIO to learn more.